Skip to content
lifestyle.faithfamilyamerica.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Valion Bio, Inc.
Valion Bio Reports Completion of 200-Liter Entolimod Production Run; Material Supplying Ongoing AFRRI Study
November 17, 2026
Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird’s National Security Conference
November 11, 2026
Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results
October 30, 2026
Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation
October 28, 2026
Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options
October 26, 2026
Valion Bio’s New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder Value
October 21, 2026
Valion Bio’s Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone
October 15, 2026
With Section 232 Tariffs Reshaping Biotech, Valion Bio’s Velocity Bioworks Capitalizes on Domestic CDMO Surge
October 14, 2026
Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers
October 9, 2026
New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod
October 5, 2026
1
2
Next Page
→